Table 1 Baseline characteristics of enrolled patients
Total n (%) | Bridging interval | P-value | ||||||
|---|---|---|---|---|---|---|---|---|
Group 1 ≤2 weeks n (%) | Group 2 2–3 weeks n (%) | Group 3 >3 weeks n (%) | Overall | ≤2 weeks vs. 2–3 weeks | 2–3 weeks vs. >3 weeks | ≤2 weeks vs. >3 weeks | ||
Number of patients | 148 | 47 | 43 | 58 | ||||
Male sex | 86 (58.1) | 28 (59.6) | 31 (72.1) | 27 (46.6) | 0.037 | 0.269 | 0.014 | 0.239 |
Age, median years (IQR years) | 68.0 (58.0–77.0) | 68.0 (55.0–78.0) | 66.0 (56.0–76.0) | 70.5 (61.8–77.0) | 0.313 | 0.545 | 0.122 | 0.427 |
BMI, median kg/m2 (IQR kg/m2) | 22.2 (20.0–24.9) | 22.8 (20.6–25.0) | 22.0 (20.2–24.8) | 22.2 (19.3–25.0) | 0.846 | 0.634 | 0.844 | 0.620 |
ASA score | 0.119 | 0.679 | 0.066 | 0.253 | ||||
ASA 1–2 | 132 (89.2) | 43 (91.5) | 43 (95.3) | 48 (82.8) | ||||
ASA 3–4 | 16 (10.8) | 4 (8.5) | 2 (4.7) | 10 (17.2) | ||||
Previous abdominal surgery | 43 (29.1) | 12 (25.5) | 13 (30.2) | 18 (31.0) | 0.829 | 0.645 | 1.000 | 0.665 |
Primary tumor location | 0.378 | 0.567 | 0.510 | 0.174 | ||||
Splenic flexure | 9 (6.1) | 4 (8.5) | 1 (2.3) | 4 (6.9) | ||||
Descending colon | 15 (10.1) | 2 (4.3) | 4 (9.3) | 9 (15.5) | ||||
Sigmoido-descending junction | 11 (7.4) | 2 (4.3) | 4 (9.3) | 5 (8.6) | ||||
Sigmoid colon | 75 (50.7) | 28 (59.6) | 24 (55.8) | 23 (39.7) | ||||
Recto-sigmoid junction | 38 (25.7) | 11 (23.4) | 10 (23.3) | 17 (29.3) | ||||
Preoperative serum CEA, median ng/ml (IQR ng/ml) (n=146) | 5.7 (3.2–13.6) | 7.8 (4.3–15.3) | 4.9 (2.5–9.8) | 5.2 (2.7–11.7) | 0.127 | 0.067 | 0.920 | 0.089 |
Adjuvant chemotherapy | 116 (78.4) | 38 (80.9) | 35 (81.4) | 43 (74.1) | 0.633 | 1.000 | 0.475 | 0.488 |
Interval from SEMS to operation, median days (IQR days) | 19.0 (12.0–25.8) | 10.0 (8.0–12.0) | 18.0 (17.0–20.0) | 28.0 (24.0–32.3) | <0.001 | <0.001 | <0.001 | <0.001 |
Pathologic results | ||||||||
T stage | 0.894 | 1.000 | 0.832 | 0.664 | ||||
1 | 1 (0.7) | 1 (2.1) | 0 (0.0) | 0 (0.0) | ||||
3 | 101 (68.2) | 32 (68.1) | 30 (69.8) | 39 (67.2) | ||||
4 | 46 (31.1) | 14 (29.8) | 13 (30.2) | 19 (32.8) | ||||
N stage | 0.139 | 0.037 | 0.139 | 0.756 | ||||
0 | 66 (44.6) | 18 (38.3) | 24 (55.8) | 24 (41.4) | ||||
1 | 54 (36.5) | 22 (46.8) | 9 (20.9) | 23 (39.7) | ||||
2 | 28 (18.9) | 7 (14.9) | 10 (23.3) | 11 (19.0) | ||||
Overall stage | 0.205 | 0.138 | 0.164 | 0.842 | ||||
2 | 66 (44.6) | 18 (38.3) | 24 (55.8) | 24 (41.4) | ||||
3 | 82 (55.4) | 29 (61.9) | 19 (44.2) | 34 (58.6) | ||||
Tumor size, median cm (IQR cm) | 6.5 (5.5–7.5) | 6.0 (5.0–6.5) | 7.0 (6.0–8.0) | 7.2 (7.0–8.0) | <0.001 | <0.001 | 0.329 | <0.001 |
Histologic grade | 0.225 | 0.105 | 0.648 | 0.501 | ||||
WD/MD | 143 (96.6) | 47 (100.0) | 40 (93.0) | 56 (96.6) | ||||
PD/Mucinous | 5 (3.4) | 0 (0.0) | 3 (7.0) | 2 (3.4) | ||||
Lymphovascular invasion | 39 (26.4) | 11 (23.4) | 15 (34.9) | 13 (22.4) | 0.316 | 0.253 | 0.184 | 1.000 |
Perinueral invasion | 97 (65.5) | 29 (61.7) | 29 (67.4) | 39 (67.2) | 0.841 | 0.661 | 1.000 | 0.682 |